INSERM 1082, Poitiers, France.
Service d'Oncologie Hématologique de Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.
Br J Haematol. 2019 Jul;186(1):54-59. doi: 10.1111/bjh.15858. Epub 2019 Mar 12.
Immunological mechanisms of treatment-free remission (TFR) in chronic myeloid leukaemia (CML) are poorly defined and, to date, no correlation between successful TFR and CD8(+) T-cell subsets has been found. We analysed a new identified human subset of CD8(+) T-cells, namely innate CD8(+) T-cells, in CML patients with TFR ≥ 2 years. We demonstrated a dramatic increase of functionally active innate CD8(+) T-cells in these patients as compared to control subjects and patients in remission under tyrosine kinase inhibitors. Moreover, we found a positive correlation between frequencies of innate CD8(+) T-cells and natural killer cells, possibly representing a new innate biomarker profile of successful TFR.
慢性髓性白血病（CML）治疗无缓解（TFR）的免疫机制尚未明确，迄今为止，尚未发现 TFR 成功与 CD8+T 细胞亚群之间存在相关性。我们分析了 TFR≥2 年的 CML 患者中一种新鉴定的 CD8+T 细胞亚群，即固有 CD8+T 细胞。与对照受试者和接受酪氨酸激酶抑制剂治疗缓解的患者相比，这些患者中功能活跃的固有 CD8+T 细胞显著增加。此外，我们发现固有 CD8+T 细胞与自然杀伤细胞之间呈正相关，这可能代表 TFR 成功的新固有生物标志物特征。
